Disclosure of large shareholding

Bergen, 10 October 2018 - reference is made to the previous announcement on 24
September 2018 regarding the disclosure of large shareholdings in relation to
the rights issue in PCI Biotech Holding ASA (the "Company" or "PCI Biotech"). In
the rights issue Myrlid AS, a company controlled by Kjetil Myrlid Aasen, has
subscribed and been allocated 1,300,000 new shares in the Company. As a result
of the transaction, Myrlid AS has become the owner of shares representing more
than 5 % of the share capital. After the transaction, Myrlid AS owns 2,260,000
shares in PCI Biotech, equal to 6.11 % of the current outstanding shares and
votes in the Company.

Aasen, including close associates, holds 3,055,000 shares in PCI Biotech, equal
to 8.26 % of the current outstanding shares and votes in the Company.

This notification is based on the share capital of PCI Biotech being NOK
110,984,670 divided on 36,994,890 shares.